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Ethylene bis-imidazoles are highly potent and
selective activators for isozymes VA and VII of
carbonic anhydrase, with a potential nootropic
effect†
Bogdan Draghici,a Daniela Vullo,b Suleyman Akocak,a Ellen A. Walker,a
Claudiu T. Supuran*b and Marc A. Ilies*a
A series of ethylene bis-imidazoles was synthesized via a novel
microwave-mediated synthesis. Biological testing on eight iso-
zymes of carbonic anhydrase (CA) present in the human brain
revealed compounds with nanomolar potency against CA VA and
CA VII, also displaying excellent selectivity against other CA iso-
zymes present in this organ.
The dynamic state of all organisms relates directly to theirmetabolic
activity. Carbon dioxide is the end product of catabolic processes of
higher vertebrates and its rapid transport and elimination are
critical for achieving fast metabolic rates. Carbonic anhydrases
(E.C. 4.2.1.1) are zinc enzymes that catalyze the reversible hydration
of CO2 under physiological conditions: CO2 + H2O2HCO3
 + H+.
Through the activity of mitochondrial isozymes, especially CA VA,
cytosolic isozymes CA I, CA II, CA VII and membrane-bound
isozymes CA IV, CA IX, CA XII, CA XIV, carbon dioxide can be
rapidly hydrated and transported from mitochondria through the
cytoplasm towards the exterior of the cell (Fig. 1).1 About 85% of
total CO2 produced in the body is transported as HCO3
 to lungs.
The above-mentioned CA isozymes are particularly important for
the brain2 which is a major CO2 producer and where the CO2/
HCO3
 buffer constitutes the main buffer in the interstitial/extra-
cellular space.3 These CA isozymes actively neutralize the steep pH
gradients (as high as 0.1 pH units) generated by neuronal discharge
that are superimposed on the normal flux of protons caused by
aerobicmetabolism.3 Strict pH control maintainsmembrane polari-
zation and the proper ionization (hence the action) of various
key neurotransmitters, such as glutamate, GABA, and dopamine.
Fluctuation of local pH has been shown to affect receptor responses
such as the NMDA receptor.4 CAs are directly involved in
cerebrospinal fluid (CSF) secretion at the level of the choroid
plexus, generating bicarbonate from CO2 and H2O, and regulat-
ing through ion hydration the volume, buffering properties,
and turnover of CSF.5
The key role played by CAs in brain homeostasis and normal
cerebral function is emphasized by CA deficiency syndrome – a
distinct genetic disorder characterized by severe pathological modi-
fications of the brain, lungs, kidneys, and bone metabolism.6
Patients with this disorder lack CA II in these tissues/organs and
blood and display a range of symptoms including cerebral calcifica-
tion, respiratory and renal tubular acidosis, inherited osteopetrosis,
and mental retardation.6 Moreover, in the neurodegenerative dis-
order of memory and cognitive function, Alzheimer’s disease, the
level of CA is significantly diminished.7 A similar decrease in the
expression level of CA was observed in the brain of older rats
relative to young animals,8 being associated with a reduced resis-
tance to dehydration, alteration in choroidal control of brain
homeostasis, and reduced cerebrospinal fluid production.
Therefore, activation of the CAs present in the brain represents a
promising and rather unexplored approach to increase brain activity,
especially memory and learning, with significant potential benefits
in older individuals or in patients affected by Alzheimer’s disease
and other forms of dementia. Sun and Alkon first suggested
that carbonic anhydrase activators (CAAs) can enhance learning
Fig. 1 Schematics of CO2 flux, from mitochondria to the cytoplasm and
to the exterior of the cell, revealing that the CA isozymes involved in the
process and the three different CO2/HCO3
 pools (extracellular (e),
cytosolic (c) and mitochondrial (m)) equilibrated by them.
a Department of Pharmaceutical Sciences and Moulder Center for Drug Discovery
Research, Temple University School of Pharmacy, 3307 N Broad Street,
Philadelphia, PA-19140, USA. E-mail: mailies@temple.edu; Fax: +1 215-707-5620;
Tel: +1 215-707-1749
b NEUROFARBA Department, Pharmaceutical Sciences Section, Universita degli
Studi di Firenze, Polo Scientifico, Via Ugo Schiff no. 6, 50019 Sesto Fiorentino,
Florence, Italy. E-mail: claudiu.supuran@unifi.it; Fax: +39-055-4573385;
Tel: +39-055-4573005
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c4cc02346c
Received 29th March 2014,
Accepted 14th April 2014
DOI: 10.1039/c4cc02346c
www.rsc.org/chemcomm
ChemComm
COMMUNICATION
Pu
bl
ish
ed
 o
n 
15
 A
pr
il 
20
14
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i F
ire
nz
e o
n 
31
/0
7/
20
15
 1
2:
46
:5
7.
 
View Article Online
View Journal  | View Issue
This journal is©The Royal Society of Chemistry 2014 Chem. Commun., 2014, 50, 5980--5983 | 5981
and memory, thus eliciting a nootropic effect.9 For example, in
the hidden-platform water maze, rats injected with the CAAs
phenylalanine or imidazole have significantly higher latencies
to escape. In further support of the role of CA in this learning
model, the CA inhibitor acetazolamide impaired memory and
prevented the improvements in learning observed after injection
of both phenylalanine and imidazole.9
Memory improvements in rodents have also been observed
through CA activation with the dipeptide carnosine.10 Finding
potent and selective CAAs with a pharmacokinetic profile that
could ensure good brain penetrability represents the critical
next step towards the generation of a potential nootropic effect.
CA activators act by speeding up the deprotonation of zinc
bound water (the rate-determining step, eqn (2) in the catalytic
mechanism), with the generation of the active form of the enzyme:11
EZn2þ OH þ CO2 Ð EZn2þ HCO3
Ð
þH2O
EZn2þ OH2 þHCO3
(1)
EZn2þ OH2 Ð EZn2þ OH þHþ -rate determining step
(2)
In the presence of an activator A, eqn (2) becomes (3):11
EZn2þ OH2 þAÐ EZn2þ OH2 A
 Ð
enzyme-activator complexes
EZn2þ OH AHþ Ð EZn2þ OH AHþ 
Ð EZn2þ OH þAHþ
(3)
Comprehensive structure–activity relationship (SAR) studies done by
us or by others11 revealed that efficient CA activators possess a
proton-shuttling group attached to a hydrophobic/amphiphilic
aromatic/heterocyclic anchor via a short, flexible linker (Chart 1,
inset). We identified imidazole as a very potent proton shuttling
moiety, in combination with various anchors (Chart 1). In the study
of CA activation with histamine 1, X-ray crystallography revealed that
the activator is anchored at the entrance of the active site cavity
through the amino group. The imidazole moiety participates in
shuttling protons between the active site and the bulk solvent, thus
acting as a second proton shuttle of the enzyme. This study
demonstrated the superiority of the imidazole structural unit
(pKa = 6–7) against the primary amino moiety (pKa = 9–10) as a
proton-shuttling group.12 Activation of CA with bis-azoles such as
bis-imidazole 2 was discovered almost simultaneously. In these
N-alkylated bis-azoles 2, one imidazole ring acts as a hydrophobic
anchor and the other one as a proton shuttle (Chart 1).13 Subsequent
studies performed by Silverman’s group on activation of CA V using
histidine analogues 4-bromoethylimidazole (4-BEI, 3), 2-chloromethyl-
imidazole (2-CMI), 4-chloromethyl-imidazole (4-CMI, 4) as covalent CA
activators confirmed the efficiency of imidazoles as CA activators.14 An
extensive SAR study on pyridinium azoles by our team15 confirmed
the imidazole moiety as the best proton shuttle (e.g., compound 5),
due to its pKa in the maximum activity range for most CA isozymes
(6.5–8.5 pKa units). The study demonstrated the efficiency of the
pyridinium moiety to anchor the activator at the rim of the active
site.15 Subsequent CA activation studies with various imidazole
derivatives (4-methylimidazole 6, L- and D-histidine (7, 8), carnosine
9 and congeners), and with the 4-(pyridinium-ethyl)imidazoles 10–12
recently synthesized by our groups confirmed this conclusion.16–18
The CAA design approach was supported by site-directed muta-
genesis studies and X-ray crystal structures of the complexes of
various CA isozymes with imidazole-based activators.17–19
The positively-charged molecules 5 and 10–12 were shown to
generate membrane-impermeant CA activators useful for studying
the physiology of membrane-bound CA isozymes. Moreover, the
same studies15,18 revealed that small differences in the structure of
activators 10–12 could trigger dramatic changes in the activation
profile of these compounds through the exploitation of the differ-
ences in the amino acids lining the active site of various isozymes.
Very recently, McKenna’s team revealed the existence of several
binding pockets for imidazole CAAs such as 4-methylimidazole 6
and its isomers.21 Encouraged by the very promising results obtained
with CAAs of type 10–12, we decided to investigate compact bis-
imidazoles 13 in which two imidazole moieties were C-linked via an
ethyl linker, attached to the 4(5)-position of the imidazole ring. In
these new CAAs, one imidazole moiety acts as the proton-shuttling
moiety, while the other imidazole anchors the activator at the rim of
the active site, being structurally related to their congeners 2 but
having the full proton shuttling capabilities conferred by a free
imidazole NH. Hydrophobic substituents of increased steric
bulk were placed in the 2-position of the imidazole ring in order
Chart 1 Evolution of CA activator design: the activation potency of representative lead compounds 1–13 at a concentration of 10 mM against different
CA isozymes,11,13,15,16,18,20 and the proposed design for the novel series of CA activators 13. The general structure of carbonic anhydrase activators is
shown in the inset.
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to facilitate the anchoring of the activator on the rim of the
different isozymes of CA. These substituents also increase
lipophilicity of the bis-imidazoles 13, thus facilitating the
crossing of the blood–brain barrier which is critical for achieving
the nootropic effect.
In terms of synthesis, bis[1H-imidazol-4(5)yl]alkanes can be pre-
pared from a-dihaloalkyldione and formamide at elevated tempera-
tures (180 1C) via Bredereck cyclization.22 However, this method is
limited to systems in which the two a-keto units in the molecule are
separated by four to eight C atoms, with longer spacers generating
higher yields. A better option for the synthesis of bis-imidazoles of
type 13 having short alkyl spacers is the strategy of Schunack et al.,23
who prepared them through the condensation of amidines with
a-dihaloalkyldione in the presence of ammonia. Since this method
requires an autoclave and generates only moderate yields even after
20 h reaction time, we tested a microwave-mediated procedure
based on this synthetic strategy.
The novel MW procedure allows the achievement of high
temperatures and moderate pressures, decreasing the reaction
time significantly. Using this procedure, we were able to generate
bis[1H-imidazol-4(5)yl]ethane derivatives 13a–e, substituted at
position 2 of the imidazole ring, from 1,6-dibromohexane-2,5-
dione 1524 and corresponding alkylamidines 1625 in the presence
of ammonia solution in methanol (Scheme 1, ESI†).
Bis-imidazoles 13a–e were subsequently tested for the acti-
vation of eight CA isozymes involved in brain homeostasis,
namely the mitochondrial hCA VA, the cytosolic hCA I, hCA II,
hCA VII and the membrane-bound hCA IV, hCA IX, hCA XII and
hCA XIV, using the CO2 hydration assay method (Table 1, see
ESI† for details).
Data from Table 1 revealed an excellent activation profile for
the new compounds. For all isozymes we identified activators
that were more potent than histamine 1, the prototype CA
activator within this class of compounds, thus validating our
new design.
The most susceptible isozymes activated with bis-imidazoles 13
were the mitochondrial isozyme CA VA and the brain cytosolic
isozyme CA VII, followed by membrane-bound hCA IV, hCA XII,
hCA IX and hCA XIV. The cytosolic isozymes hCA I and hCA II were
the least susceptible to be activated with this class of compounds.
Importantly, in the case of hCA VA and hCA VII, we were able
to identify activators with nanomolar potency. For these isozymes
the increase in steric bulk of the substituents placed in position 2
of the imidazole rings generally caused a decrease in the potency
of the activators, probably due to the limited space available in the
active site and the decreased mobility of the heterocyclic rings
substituted with bulky substituents such as iPr (13d) and Ph (13e).
The most potent activators were 13a (R = H), with a KA = 21 nM for
hCA VA, KA = 15 nM for hCA VII and 13b (R = CH3) with a KA =
9 nM for hCA VA and KA = 20 nM for hCA VII. Importantly, these
activators were three orders of magnitude more selective for hCA VA
and hCA VII as compared with the other cytosolic and membrane-
bound CA isozymes tested (Table 1).
Thus, bis-imidazoles 13 displayed only micromolar potency
against membrane-bound hCA IV, hCA XII, hCA IX and hCA XIV
and cytosolic isozymes hCA I and hCA II. Moreover, for these
isozymes the increase in steric bulk of substituents placed in
position 2 of the imidazole rings in compounds 13 was not
dramatically decreasing the activation potency. This particular
activation profile may suggest a different binding location of
bis-imidazoles 13 in the active sites of hCA VA and hCA VII as
compared with the other CA isozymes tested.
The recent identification of multiple binding sites for dif-
ferently substituted imidazoles within the active site of hCA II21
supports this hypothesis. Work is in progress to shed light on
the structural origin of the potency and selectivity of these
novel CA activators.
In conclusion, we are proposing a novel set of nanomolar CA
activators that act selectively on CA VA and CA VII, key CA isozymes
involved in brainmetabolism. Their potency and selectivity against
other CA isozymes present at the level of the brain, together with
their optimum lipophilicity recommend them as novel probes for
elucidation of the role of CA VA and CA VII in brain physiology and
potential modulators of learning, memory and cognition.
This work was supported by TUSP Dean’s Office and an EU
Grant (Dynano).
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